INTENSIVE INSULIN THERAPY J. Robin Conway M.D. Diabetes Clinic, Smiths Falls, ON 1-800-717-0145 Objectives • Optimize diabetes management • Assist you in initiating insulin in your.

Download Report

Transcript INTENSIVE INSULIN THERAPY J. Robin Conway M.D. Diabetes Clinic, Smiths Falls, ON 1-800-717-0145 Objectives • Optimize diabetes management • Assist you in initiating insulin in your.

INTENSIVE INSULIN
THERAPY
J. Robin Conway M.D.
Diabetes Clinic, Smiths Falls, ON
1-800-717-0145
1
Objectives
• Optimize diabetes management
• Assist you in initiating insulin in your office
– When to start insulin therapy?
– Insulins, doses, delivery options
– Patient training
2
Challenges in Initiating Insulin?
1. Patient attitudes
– Fear of needles
– Insulin viewed as a threat by patient & physician
– Hypoglycemia
2. Physician Attitudes
– Discomfort with insulin
• Lack of knowledge and experience
– Fear of needles
3
Type 1 Diabetes:
• Impaired or absent ß cell function:
–  insulin secretion
• Normal insulin action:
–  insulin sensitivity
• The insulin deficiency results in
unacceptable blood glucose control
4
Type 2 Diabetes: Double Impairment
• Impaired ß cell function:
–  insulin secretion
• Impaired insulin action:
–  insulin resistance
• Results in unacceptable blood glucose
control
5
Type 1 & 2 Diabetes: Key Concepts
• Minimizing the complications of diabetes
requires:
– Early diagnosis and treatment of diabetes
– Maintaining HbA1C level < 7%
• Achieving HbA1C < 7% requires control of
post-prandial and fasting hyperglycemia
6
CDA Guidelines (for glycemic control)
Normal
A1C level
Preprandial
glycemia
Optimal
(0.04-0.06) (< 0.07)
3.5-6.1
4-7
(mmol/L)
Postprandial
glycemia
4.4-7.8
7-11
(mmol/L)
Haars s et al., CMAJ 2003; 159 (Suppl.): S1-29. Gerstein, H.C. et al. CDA views on the UKPDS and revision of the
guidelines affected by the results of this study.
7
Steps to Glycemic Control
• Establish glycemic objectives
– Target fasting and post-prandial glycemia
• Diet counseling with exercise component
• Diabetes education for every patient
• Pharmacological treatment; oral and insulin
8
Patient Counselling Topics
A.Review symptoms and treatment of
hypoglycemia
B.Proper training and correct use of glucose
monitor
C.Target desired glycemic levels for each
patient
9
A. Hypoglycemia
• Definition: Glycemia < 3.8 mmol
• Patients may experience hypoglycemia at
different glycemic levels
10
Symptoms of Hypoglycemia
Mild
• < 3.3 mmol/L
• Neurovegetative
symptoms
–
–
–
–
–
–
–
Sweating
Trembling
Palpitations
Anxiety
Tingling
Pallor
Hunger
Moderate to Severe
• < 2.8 mmol/L
• Symptoms of glucopenia
–
–
–
–
–
–
–
–
Confusion
Visual disturbances
Weakness
Speech disorder
Behavioural disorder
Drowsiness
Coma
Convulsions
11
Preventing Hypoglycemia
• Check BG 4-6 times per day
• Carry glucose tablets
• Have Glucagon Kit available
12
Preventing Hypoglycemia
• Test before driving and ideally 1 hour later
(target: over 5.5 mmol/L)
• Perform two SMBG 30 minutes apart prior to
bedtime (confirming rising or falling BG)
• When drinking alcohol, perform SMBG hourly
• With exercise, perform SMBG pre- and postexercise
• If hypoglycemia episodes persist, raise target
glucose levels
13
Hypoglycemia Treatment
Guidelines
The Rule of 15
• If BG is 4 mmol/L or below
– Treat with 15 grams of carbohydrates (glucose
tabs)
– Check BG in 15 minutes, and if not above 4
mmol/L, repeat treatment
Glucagon
• Current emergency kit readily available and
knowledgeable person trained to administer
14
Preventing
Hyperglycemia and DKA
• Monitor BG 4-6 times per day
• Use Correction Boluses when appropriate
15
Hyperglycemia Treatment Guidelines
The Key to Preventing DKA
1st BG over 14 mmol/L:
• Take a correction bolus, check again
in 1 hour
• Call physician immediately or go to ER if
nausea and vomiting are present
16
B. Patient Training
• Training by a multidisciplinary team at
DEC is IDEAL for:
–
–
–
–
Diet counseling
Education on the injection sites
Education on the various injection devices
Evaluation of the patient’s support network
• Other resources may exist for training, i.e.
retail pharmacy
17
C. Blood Glucose Monitoring
• To adjust the insulin treatment
• To detect or confirm hypoglycemia or severe
hyperglycemia
• To adjust treatment to the circumstances of daily
life using an insulin scale prescribed by the
attending physician
• To improve patient safety and increase motivation
to comply with treatment
18
Ideal Testing Frequency
• Stable type 2
– 1-2 readings/day
• Type 1 or Unstable type 2
– 3-8 readings/day
• Important to stress the need to vary testing
times
– AC, PC, h.s. and prn during the night
19
Injection Tools and Options
• Durable delivery devices • Disposable: multidose,
– Novolin-Pen® 3
prefilled (3.0 mL)
– Novolin-Pen® Junior
– NovolinSet® (NPH,
– InDuo®
Toronto, 30/70 )
– Innovo®
®N
–
Humulin
– HumaPen®
• Insulin pumps
• Syringes
20
Advancing Insulin Therapy Through
Device Innovation
21
Goal of Insulin Therapy
We are trying to duplicate
how the pancreas works in
releasing insulin for
someone who doesn’t
have diabetes
22
Non-diabetic Insulin and Glucose
Profiles
Breakfast
Lunch
Supper
75
Insulin
(µU/mL)
50
Insulin
25
Basal insulin
0
9.0
Glucose
6.0
Glucose
(mmo/L) 3.0
Basal glucose
0
7 8 9 10 11 12 1 2 3 4 5 6 7 8 9
a.m.
p.m.
Time of Day
23
Insulin Preparations
Rapid-acting Aspart (NovoRapid®)
Vial and cartridge
Lispro (Humalog®)
Short-acting
(regular)
Novolin®ge Toronto
Humulin® R
Vial and cartridge
Prolonged
action
Start 30-60
min.
Peak 4 hr
Vial and cartridge
Intermediate
Start < 15
min.
Novolin®ge NPH
Humulin® N
Start 1.5
hrs
Peak 7 hr
Humulin® U
vial only
Lantus (Glargine)
Levemir (Detemir)
vial only
cartridge
Start 3-4
hrs.
Peakless 24
Insulin PreMixes
• Regular + intermediate
– Novolin® 10/90, 20/80, 30/70, 40/60, 50/50
– Humulin® 30/70, 20/80
• Analogue Pre-Mix
– Humalog® 25/75 (insulin lispro protamine
suspension)
– NovoMix 30* (protaminated insulin aspart)
* Not available
25
Normal Blood Glucose Levels
Blood Glucose (mmols)
1086420
8am
noon
6pm
2am
4am
8am
Time
26
Normal Blood Glucose Levels
Blood Glucose (mmols)
1086420
8am
noon
6pm
2am
4am
8am
Time
27
Blood Glucose (mmols)
Two injections/day
108642-
R or H + N in AM
R or H + N at Supper
0
8am
noon
6pm
2am
4am
8am
Time
28
Blood Glucose (mmols)
10-
Three injections/day
8642-
R or H + N in
AM
R or H at
Supper
N before bed
0
8am
noon
6pm
2am
4am
8am
Time
29
Blood Glucose (mmols)
Four injections/day
108642-
R or H at every meal
N or U once or twice/day
0
8am
noon
6pm
2am
4am
8am
Time
30
Blood Glucose (mmols)
Continuous Infusion
108642-
0
8am
noon
6pm
2am
4am
8am
Time
31
Limitations of Regular Human
Insulin
• Slow onset of activity
– Should be given 30 to 45 minutes before meal
• Inconvenient for patients
• Long duration of activity
– Lasts up to 12 hours
• Potential for late postprandial
hypoglycaemia (4-6 hours)
– Need for additional snack
32
Adherence to Injection Recommendation
(Canada)
"When do you inject your insulin?"
% of Respondents
100
42%
32%
22%
4%
0
30–45 min
15–30 min
0–15 min
Before
1998 Roper Starch Canada, Premix Insulin Using
Meal
0–15 min
After
33
Dissociation of Regular Human
Insulin
Regular Human Insulin
10-3 M
10-3 M

formulation
10-5 M

hexamers
10-8 M
peak time
2-4 hr

dimers
monomers
capillary membrane
34
Objectives for the Development of ShortActing Insulin Analogues
• Modify time action to address
– Postprandial hyperglycemia
– Hypoglycemia
• Improve safety and convenience
35
Whats’ new in type 1 diabetes
treatment?
• Insulin analogues.
• Physiological insulin replacement
• Aggressive “intensive” management
–
–
–
–
4 injections per day
Insulin infusion pumps
Continuous glucose monitoring systems
Integrated technologies for monitoring control
36
Non-diabetic Insulin and Glucose
Profiles
Breakfast
Lunch
Supper
75
Insulin
(µU/mL)
50
Insulin
25
Basal insulin
0
9.0
Glucose
6.0
Glucose
(mmo/L) 3.0
Basal glucose
0
7 8 9 10 11 12 1 2 3 4 5 6 7 8 9
a.m.
p.m.
Time of Day
37
NovoRapid® (insulin aspart)
Time-Action Profile
0
2
4
6
8
10
12
14
16
18
20
22
24
NovoRapid®
Rapid-acting insulin analogue
Onset: 10-20 minutes
Maximum effect: 1-3 hours
Duration: 3-5 hours
38
Goal of Insulin Therapy
We are trying to duplicate
how the pancreas works in
releasing insulin for
someone who doesn’t
have diabetes
39
Insulin Therapy Options
• MDI therapy
– 0.5 units/kg = total daily dose
– 4x/day 40% NPH @ hs and 60% rapid acting
analogue ac meals
– For patients with significant complications (i.e.
renal failure, foot infections, CVD, etc…)
40
Basal Insulin
In someone without diabetes, the
pancreas delivers a small amount of
insulin continuously to cover the body’s
non-food related insulin needs.
41
Bolus Insulin
The amount of insulin required to
cover the food you eat.
Fast-acting or Short-acting
(clear) insulin works as a
Bolus Insulin
42
Why count carbs?
• More precise way of measuring the
impact of a meal on blood sugar
• Lets you decide how much insulin is
needed to “cover” the meal
• Greater flexibility -eat what you want,
when you want to eat it
43
Fine Tuning: Bolus Doses
• Carbohydrate counting or pre-determined
meal portion
• Individualized insulin to carbohydrate dose
or insulin to meal dose
• Adjust bolus based on post-meal BGs or
next pre-meal BG
44
Fine Tuning: Basal Rate
• Monitor BG pre-meal, post-meal,
bedtime, 12am, and 2-4am
• Test fasting BG with skipped meals
• Adjust nighttime basal based on
2-4am and pre-breakfast BG
• Adjust basal by 0.1 u/hr to avoid
over-correction
45
Novolin®ge 30/70
Time-Action Profile
Premixed insulin
Onset: 0.5 hour
Maximum effect: 2-12 hours
Duration: 24 hours
46
30/70 - Twice/day
47
30/70 Dose Calculation
•
•
•
•
Weight = 80 kg
80 kg x 0.3 U/kg = 24 U
2/3 in the AM = 16 Units
1/3 at supper = 8 Units
48
Dosage Changes
• Change insulin dose so that peak of action
corresponds to most abnormal value (pre-meal)
• If all values are abnormal - start with fasting
glycemia followed by lunch, supper and bedtime
• Change the dose by increments of 1-4 U
• Not more than twice/week
• Monitor for PATTERNS in hypoglycemia
49
Full Range of Novo Nordisk Insulins
0
2
4
6
8
10
12
14
16
18
20
22
24
NovoRapid® Penfill®
Rapid-acting human
insulin analogue
(insulin aspart)
Novolin®ge Toronto Penfill®
Short-acting insulin
(insulin injection, human biosynthetic)
Novolin®ge NPH Penfill®
Intermediate-acting
Insulin (insulin injection, human
biosynthetic)
Onset: 10-20 minutes
Maximum effect: 1-3 hours
Duration: 3-5 hours
Onset: 0.5 hour
Maximum effect: 1-3 hours
Duration: 8 hours
Onset: 1.5 hours
Maximum effect: 4-12 hours
Duration: 24 hours
50
Somogyi Effect
• Hyperglycemia secondary to asymptomatic
hypoglycemia (especially at night)
• If the insulin is increased in evening, the
problem worsens
• Check capillary glycemia around 3 a.m. to
eliminate hypoglycemia
• In this case, reduce the h.s. NPH
51
Follow-Up: The Patient’s Role
Every Day
Every 3 months
• Check BG 4-6 times a day,
and always before bed
• Follow hypoglycemia
guidelines
• Follow hyperglycemia
guidelines
• Visit healthcare provider even if feeling well
• Review log book and pump
settings with physician
• Get an A1c test
Every month


Review DKA prevention
Check BG
-
3am (overnight)
1 and/or 2-hour post-meal BG for all meals on a given day
52
Case Study #1
• Patient R.M., DM for 9 years
• BMI = 34,
• Meds: metformin 1000 mg BID and
glyburide 10 mg BID, Avandia 8 mg OD
• HbA1C is 9.5 %, FBS 11.8
What is the next step?
53
Case Study #2
• Patient K.G., DM for 15 years
• BMI = 23
• Meds: Metformin 1000 mg BID and
Gluconorm 2 mg TID
• HbA1C = 8.5%, FBS 7.4
• Post MI
What is the next step?
54